hers compounded semaglutide safety Hims & Hers' Super Bowl ad turns up the heat on GLP-1 battle Weight Loss | Take Care

N Engl J Med 2019;381:84151.PubMed 37

A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Inoue, K., Hisatomi, A., Umeda, F

People using insulin or sulfonylureas need extra caution with any therapy that can improve glucose levels, because hypoglycemia (low blood sugar) may become a concern

GLP-1 receptor agonist therapy represents a medically supervised, evidence-based approach to long-term weight management targeting the biological root of appetite and metabolism for sustainable, clinically guided results Most patients notice appetite changes within 24 weeks

A 2023 register-based study by Tang and colleagues followed 88,000 older adults with type 2 diabetes for 10 years and observed a 30% lower risk of dementia compared to those taking sulfonylureas